HCV Virus and Lymphoid Neoplasms
Hepatitis C virus (HCV) is one of the viruses known to cause hepatic cancer. HCV is also believed to be involved in malignant lymphoma. In this paper, we investigated characteristics of malignant lymphoma cases that were anti-HCV antibody (HCV-Ab) positive. We were able to perform pathological exami...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2011/717951 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850232591724052480 |
|---|---|
| author | Yutaka Tsutsumi Shinichi Ito Reiki Ogasawara Kazuhiro Kudo Junji Tanaka Masahiro Asaka Masahiro Imamura |
| author_facet | Yutaka Tsutsumi Shinichi Ito Reiki Ogasawara Kazuhiro Kudo Junji Tanaka Masahiro Asaka Masahiro Imamura |
| author_sort | Yutaka Tsutsumi |
| collection | DOAJ |
| description | Hepatitis C virus (HCV) is one of the viruses known to cause hepatic cancer. HCV is also believed to be involved in malignant lymphoma. In this paper, we investigated characteristics of malignant lymphoma cases that were anti-HCV antibody (HCV-Ab) positive. We were able to perform pathological examinations on 13 out of 14 HCV-positive cases. Of these, lymphoid tissues of 10 stained positive for HCV-Ab. There was no significant correlation between the degree of HCV staining and the rate of recurrence or resistance to treatment. However, there did appear to be a consistent decrease in the amount of HCV-RNA between pre- and posttreatment among HCV-Ab-positive cases; that is, treatment-resistant cases that exhibited resistance from the first treatment and recurrent cases more frequently had a higher HCV level at treatment termination compared to the pretreatment level. This suggests that the HCV virus either accelerates oncogenesis by direct interaction with B cells or indirectly affects lymphoma prognosis. |
| format | Article |
| id | doaj-art-0b04889c33cf4562bcc89e2c4a32e7ce |
| institution | OA Journals |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-0b04889c33cf4562bcc89e2c4a32e7ce2025-08-20T02:03:08ZengWileyAdvances in Hematology1687-91041687-91122011-01-01201110.1155/2011/717951717951HCV Virus and Lymphoid NeoplasmsYutaka Tsutsumi0Shinichi Ito1Reiki Ogasawara2Kazuhiro Kudo3Junji Tanaka4Masahiro Asaka5Masahiro Imamura6Department of Hematology, Hakodate Municipal Hospital, 1–10-1 Minato-cho, Hakodate 041-8680, JapanDepartment of Hematology, Hakodate Municipal Hospital, 1–10-1 Minato-cho, Hakodate 041-8680, JapanDepartment of Hematology, Hakodate Municipal Hospital, 1–10-1 Minato-cho, Hakodate 041-8680, JapanDepartment of Clinical Pathology, Hakodate Municipal Hospital, 1–10-1 Minato-cho, Hakodate 041-8680, JapanDepartment of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo 60-8638, JapanDepartment of Gastroenterology, Hokkaido University Graduate School of Medicine, Sapporo 60-8638, JapanDepartment of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo 60-8638, JapanHepatitis C virus (HCV) is one of the viruses known to cause hepatic cancer. HCV is also believed to be involved in malignant lymphoma. In this paper, we investigated characteristics of malignant lymphoma cases that were anti-HCV antibody (HCV-Ab) positive. We were able to perform pathological examinations on 13 out of 14 HCV-positive cases. Of these, lymphoid tissues of 10 stained positive for HCV-Ab. There was no significant correlation between the degree of HCV staining and the rate of recurrence or resistance to treatment. However, there did appear to be a consistent decrease in the amount of HCV-RNA between pre- and posttreatment among HCV-Ab-positive cases; that is, treatment-resistant cases that exhibited resistance from the first treatment and recurrent cases more frequently had a higher HCV level at treatment termination compared to the pretreatment level. This suggests that the HCV virus either accelerates oncogenesis by direct interaction with B cells or indirectly affects lymphoma prognosis.http://dx.doi.org/10.1155/2011/717951 |
| spellingShingle | Yutaka Tsutsumi Shinichi Ito Reiki Ogasawara Kazuhiro Kudo Junji Tanaka Masahiro Asaka Masahiro Imamura HCV Virus and Lymphoid Neoplasms Advances in Hematology |
| title | HCV Virus and Lymphoid Neoplasms |
| title_full | HCV Virus and Lymphoid Neoplasms |
| title_fullStr | HCV Virus and Lymphoid Neoplasms |
| title_full_unstemmed | HCV Virus and Lymphoid Neoplasms |
| title_short | HCV Virus and Lymphoid Neoplasms |
| title_sort | hcv virus and lymphoid neoplasms |
| url | http://dx.doi.org/10.1155/2011/717951 |
| work_keys_str_mv | AT yutakatsutsumi hcvvirusandlymphoidneoplasms AT shinichiito hcvvirusandlymphoidneoplasms AT reikiogasawara hcvvirusandlymphoidneoplasms AT kazuhirokudo hcvvirusandlymphoidneoplasms AT junjitanaka hcvvirusandlymphoidneoplasms AT masahiroasaka hcvvirusandlymphoidneoplasms AT masahiroimamura hcvvirusandlymphoidneoplasms |